[go: up one dir, main page]

SI1951314T1 - Sistemi za administracijo zdravil - Google Patents

Sistemi za administracijo zdravil

Info

Publication number
SI1951314T1
SI1951314T1 SI200631192T SI200631192T SI1951314T1 SI 1951314 T1 SI1951314 T1 SI 1951314T1 SI 200631192 T SI200631192 T SI 200631192T SI 200631192 T SI200631192 T SI 200631192T SI 1951314 T1 SI1951314 T1 SI 1951314T1
Authority
SI
Slovenia
Prior art keywords
delivery systems
signal substance
support
drug
specific
Prior art date
Application number
SI200631192T
Other languages
English (en)
Inventor
Matthias Seiler
Norbert Windhab
Manfred Stickler
Hans-Ulrich Petereit
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of SI1951314T1 publication Critical patent/SI1951314T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SI200631192T 2005-10-25 2006-10-25 Sistemi za administracijo zdravil SI1951314T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005051366A DE102005051366A1 (de) 2005-10-25 2005-10-25 Drug Delivery Systeme
EP06828863A EP1951314B1 (de) 2005-10-25 2006-10-25 Drug delivery systeme
PCT/EP2006/010301 WO2007048599A2 (de) 2005-10-25 2006-10-25 Drug delivery systeme

Publications (1)

Publication Number Publication Date
SI1951314T1 true SI1951314T1 (sl) 2012-02-29

Family

ID=37887882

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631192T SI1951314T1 (sl) 2005-10-25 2006-10-25 Sistemi za administracijo zdravil

Country Status (16)

Country Link
US (2) US8313778B2 (sl)
EP (1) EP1951314B1 (sl)
JP (1) JP5065281B2 (sl)
KR (1) KR101365765B1 (sl)
CN (2) CN103816546A (sl)
AT (1) ATE526040T1 (sl)
AU (1) AU2006308083B2 (sl)
BR (1) BRPI0617775B8 (sl)
CA (1) CA2625856C (sl)
DE (1) DE102005051366A1 (sl)
ES (1) ES2373118T3 (sl)
HK (1) HK1198429A1 (sl)
IL (1) IL190697A (sl)
PL (1) PL1951314T3 (sl)
SI (1) SI1951314T1 (sl)
WO (1) WO2007048599A2 (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940905B1 (de) * 2005-10-25 2010-08-11 Evonik Degussa GmbH Präparate umfassend hyperverzweigte polymere
CN100512752C (zh) * 2007-01-12 2009-07-15 天津市先石光学技术有限公司 光程可选择的无创人体成分检测方法及检测装置
EP1982698A1 (de) * 2007-04-18 2008-10-22 Evonik Degussa GmbH Präparate zur gesteuerten Freisetzung von bioaktiven Naturstoffen
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
ES2319158B1 (es) 2008-12-23 2010-01-26 Grifols, S.A Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.
CA3149284A1 (en) 2009-12-15 2011-07-14 Incept, Llc Implants and biodegradable fiducial markers
WO2012031245A1 (en) * 2010-09-03 2012-03-08 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
US8603373B2 (en) * 2010-11-04 2013-12-10 Ricoh Company, Ltd. Method for producing particles, method for producing toner, and apparatus for producing particles
WO2012069089A1 (en) 2010-11-26 2012-05-31 Evonik Röhm Gmbh Human lactoferrin derived peptide for use as an antigen masking agent
US8360765B2 (en) 2011-01-07 2013-01-29 Covidien Lp Systems and method for forming a coaxial implant
JP2015504631A (ja) 2011-11-14 2015-02-12 京セラ株式会社 マクロセル通信リソースを使用する端末間サウンディング参照信号の送信
SG11201507142QA (en) 2013-03-15 2015-10-29 Techulon Inc Antisense molecules for treatment of staphylococcus aureus infection
WO2014144423A2 (en) 2013-03-15 2014-09-18 Techulon Inc. Antisense molecules for treatment of staphylococcus aureus infection
CN103665384B (zh) * 2013-05-20 2016-10-05 中国药科大学 新型阳离子接枝共聚物及多重复合非病毒基因载体制备方法和应用
US9198973B2 (en) * 2013-06-17 2015-12-01 Fundacion Fraunhofer Chile Research PAMAM, spacer molecule and cafestol polymers
US20170073465A1 (en) * 2014-02-28 2017-03-16 Michigan Molecular Institute Sustained release composition using biobased biodegradable hyperbranched polyesters
KR102203615B1 (ko) * 2014-03-24 2021-01-18 한국생명공학연구원 표면작용기 조절을 통해 망막층 내로의 침투가 용이한 덴드리머 기반의 망막 질환 치료용 약물 전달체
CA2950339C (en) * 2014-05-28 2022-03-29 Evonik Rohm Gmbh Coated calcium phosphate nanoparticles comprising a cationic polymer layer
WO2018160791A1 (en) 2017-03-03 2018-09-07 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
KR20210008496A (ko) * 2018-05-08 2021-01-22 에보니크 오퍼레이션즈 게엠베하 생흡수성 폴리에스테르, 친수성 중합체 및 아실화된 인간 락토페린-유래 펩티드를 포함하는 나노입자
EP4081576B1 (en) * 2019-12-23 2024-11-06 Evonik Operations GmbH Dual-crosslinked hydrogel and preparation method thereof
CN116693697B (zh) * 2023-06-02 2024-03-19 深圳市瑞鑫医药开发有限公司 一种用于缓解视疲劳的滴眼液

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006833A1 (en) * 1995-08-11 1997-02-27 Dendritech, Inc. Hyper comb-branched polymer conjugates
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
GB2364127B (en) 2000-06-29 2004-08-25 Univ London Method and apparatus for monitoring structural fatigue and use
GB0019412D0 (en) 2000-08-08 2000-09-27 Univ York New imaging agent
AU2002222557A1 (en) 2000-11-29 2002-06-11 Morinaga Milk Industry Co., Ltd. Interferon therapeutic effect-potentiating agents
WO2003051281A2 (en) 2001-10-17 2003-06-26 Ganado Research, L.L.C. Composition and method to treat viral bacterial and parasitic infections and infestations
US6916483B2 (en) * 2002-07-22 2005-07-12 Biodynamics, Llc Bioabsorbable plugs containing drugs
NZ574134A (en) * 2003-02-13 2011-03-31 Dimitrios Tsiourvas Multifunctional dendrimers and hyperbranched polymers as drug and gene delivery systems
WO2005055949A2 (en) * 2003-12-09 2005-06-23 The Children's Hospital Of Philadelphia Sustained release preparations composed of biocompatible complex microparticles
EP1976547A1 (en) * 2005-11-11 2008-10-08 Vascular Biosciences R-ras activity in vascular regulation
WO2007076904A1 (en) 2005-12-30 2007-07-12 Evonik Röhm Gmbh Peptides useful as cell-penetrating peptides

Also Published As

Publication number Publication date
EP1951314B1 (de) 2011-09-28
KR20080059400A (ko) 2008-06-27
KR101365765B1 (ko) 2014-02-20
WO2007048599A2 (de) 2007-05-03
JP5065281B2 (ja) 2012-10-31
ATE526040T1 (de) 2011-10-15
US20090011038A1 (en) 2009-01-08
US8313778B2 (en) 2012-11-20
US20130273163A1 (en) 2013-10-17
CN101296709A (zh) 2008-10-29
BRPI0617775A2 (pt) 2011-08-09
CA2625856C (en) 2014-01-28
PL1951314T3 (pl) 2012-02-29
IL190697A (en) 2015-04-30
JP2009512722A (ja) 2009-03-26
AU2006308083A1 (en) 2007-05-03
DE102005051366A1 (de) 2007-04-26
EP1951314A2 (de) 2008-08-06
CN103816546A (zh) 2014-05-28
IL190697A0 (en) 2008-11-03
BRPI0617775B8 (pt) 2021-05-25
HK1198429A1 (en) 2015-04-24
CA2625856A1 (en) 2007-05-03
WO2007048599A3 (de) 2008-03-20
AU2006308083B2 (en) 2012-07-19
BRPI0617775B1 (pt) 2019-10-22
ES2373118T3 (es) 2012-01-31
US9480654B2 (en) 2016-11-01

Similar Documents

Publication Publication Date Title
IL190697A0 (en) Drug-delivery system
WO2004064618A3 (en) Methods for making oxidation resistant polymeric material
PT1313453E (pt) Vectores particulados destinados a melhorar a absorção oral de princípios activos
IL211084A (en) One-time use unit for cardiovascular system
BR0203650A (pt) Estentor de auto-articulação
WO2004104021A3 (en) Controlled release of active agents utilizing repeat sequence protein polymers
BR0308486A (pt) Composição tópica compreendendo um ciclofrutano, um veìculo e uma droga
WO2000021572A3 (en) Hydrogels and water soluble polymeric carriers for drug delivery
DE50009646D1 (de) Bicyclische heterocyclen, verfahren zu ihrer herstellung und ihre verwendung als herbizide und pharmazeutische mittel
MX2010004400A (es) Polimeros de multiples brazos dirigidos a la hidroxiapatita y conjugados de estos.
DE60013616D1 (de) Abwasserreinigung bei viehzuchtanlagen
EP2296693A4 (en) COMPOUNDS FOR REINFORCING THE ANTIBACTERIAL EFFECT OF MYELOPEROXIDASE AND METHOD OF USE THEREOF
WO2004072265A3 (en) Methods for monitoring drug activities in vivo
MX2007004738A (es) Inhibidores de mif.
DE59902006D1 (de) Wirkstoffhaltige aromatische copolyester
AU2006268143A8 (en) Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as chitosan
BR0008732A (pt) Métodos para detectar atividade de caspase derivada de membrana e seus moduladores
ATE273615T1 (de) Desinfektionsmittel
WO2008073849A3 (en) Enclosed track system for a fall protection system
MX2007006670A (es) Acondicionador del suelo.
WO2012061360A3 (en) Pharmaceutical compositions
BR9917391B1 (pt) processo para a polimerização de uma ou mais olefinas, e, processo para estreitar a distribuição do peso molecular de um polìmero, compreendendo uma ou mais olefinas.
BR0307241A (pt) Composição sólida para condicionamento de tecido
BR0311319A (pt) Sistema e método para concretização de unidades de carga
ATE418613T1 (de) Antimikrobielle zusammensetzungen